ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "hydroxychloroquine and quality improvement"

  • Abstract Number: 323 • 2019 ACR/ARP Annual Meeting

    Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients

    Thein Swe1 and Andras Perl 1, 1SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: Hydroxychloroquine (HCQ) induced retinal toxicity remains a major concern because it can lead to irreversible damage to retinal pigment epithelium and blindness. American Academy…
  • Abstract Number: 1243 • 2018 ACR/ARHP Annual Meeting

    A Quality Improvement Initiative to Increase Adherence to Hydroxychloroquine Dosing Guidelines at an Academic Medical Center

    Ryan Jessee, Stephanie L. Giattino, Atul Kapila, Katherine Kaufman, Jon Golenbiewski, Brian J. Andonian, David Leverenz and Lisa Criscione-Schreiber, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC

    Background/Purpose: In 2016, the American Academy of Ophthalmology published revised guidelines on HCQ dosing, recommending a maximum daily dose of 5mg/kg actual body weight as…
  • Abstract Number: 1244 • 2018 ACR/ARHP Annual Meeting

    Hydroxychloroquine Quality Improvement Project at UF Health Jacksonville Rheumatology Clinics

    Shameik Brooks, Gurjit Kaeley and Lanh Dang, UF Health Jacksonville, Jacksonville, FL

    Background/Purpose: Hydroxychloroquine (HCQ) is a treatment option for lupus erythematosus and rheumatoid arthritis. The risk of retinopathy in the first 5 years of therapy is…
  • Abstract Number: 2034 • 2017 ACR/ARHP Annual Meeting

    New Guidelines on Hydroxychloroquine Dosage – Where Are We?

    Shriyanka Jain1 and John Waterman2, 1Division of Rheumatology, University of Connecticut, School of Medicine, Farmington, CT, 2Rheumatology, Connecticut VA Healthcare System, Newington, CT

    Background/Purpose: Hydroxychloroquine (HCQ) is a widely-used medication in many rheumatologic conditions. The most worrisome toxicity is irreversible damage to retinal pigment epithelium which can lead…
  • Abstract Number: 1032 • 2015 ACR/ARHP Annual Meeting

    Adherence Patterns to American Academy of Ophthalmology Guidelines for Hydroxychloroquine Baseline Screening: Quality Assurance Assessment Utilizing Highmark Claims Data

    Christina Payne1, Patricia Gladowski2, James Byers Jr.2, Amy Tang3 and Mary Chester M. Wasko4, 1Allegheny General Hospital Department of Medicine, Allegheny Health Network, Pittsburgh, PA, 2Enterprise Knowledge Discovery, Highmark Health, Pittsburgh, PA, 3Asthma, Allergy and Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 4Lupus Center, Pittsburgh, PA

    Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial agent used commonly to treat selected autoimmune rheumatic diseases because of its therapeutic benefits, low cost, and favorable safety…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.